Introduction
Bacterial or viral infections are associated with inflammatory responses in the host that result in cytokine release from innate immune cells. As an essential part of the innate immune system, panels of Toll-like receptors (TLRs) have been identified as receptors that recognize pathogen associated molecular patterns (PAMPs) (28, 55, 56) and trigger cytokine release as part of the first line immune defense (52). Several of these cytokines including IL-6, TNF and IL-1 have been implicated in sickness syndrome including fever, anorexia, adipsia and depressed mobility. Studies examining the potential contribution of TLRs to a systemic sickness response have largely focused on the TLR4 ligand lipopolysaccharide (LPS) (11, 26, 57, 58).
Administration of LPS can mimic systemic inflammatory signals, which can result in anorexia, adipsia, and changes in temperature (7, 23, 57). The potential contributions of other TLR ligands have not yet been fully established.
Natural agonists for other TLRs have been identified as microbial or viral components, including peptidoglycans (TLR2) (49), viral RNA (TLR3) (1), flagellin (TLR5) (18) , and Although administration of 1V136 might have beneficial anti-viral effects, the potential for inducing a sickness syndrome also exists. Except for TLR3, all of the TLRs and IL-1 utilize the intracellular adaptor protein MyD88 to transmit pro-inflammatory signals (29, 59 ).
This common intermediary suggests that TLR7 signaling will result in similar physiologic responses as LPS and IL-1 stimulation. The signaling cascades that stem from TLR-ligation result in the nuclear translocation of transcription factors that induce the production of type I IFN, IL-6, TNF and cyclo-oxygenase-2 (COX2). All of these factors have been described in the sickness response (4, 10).
In this study, we demonstrate that the mucosal administration of the TLR7 agonist, 1V136, transiently reduces food-intake, and induces weight loss in mice, accompanied by hypothermia. Mice that lack lymphocytes have an enhanced anorexic response, suggesting that saline between 8 and 9 am and were placed in cages with pre-weighed chow. LPS was dissolved in saline and 2µg per mouse was i.p. administered (27) . For pharmacologic inhibition studies mice were i.p. injected with dexamethasone (3mg/kg), histamine receptor antagonists (CM, or CIM)(20mg/kg) (12), or CROM (400mg/kg) (32) in 200µl saline 1h prior to administration of 1V136. Food intake was recorded by weighing the food before treatment and 24h after 1V136 administration using a scale, model VIC511 (Acculab, Edgewood, NY). Percent food intake is expressed relative to mean food intake for a contemporaneous control group of the same strain (change in weight of food for treated mouse )/( mean change in weight of food from DMSO control mice of the same strain) x 100. In some experiments water intake was measured using metabolic cages (Braintree Scientific, Braintree, MA). Blood was collected via retroorbital bleed using heparinized Natelson capillary tubes (Fischer Scientific, Pittsburgh, PA). Serum was separated by centrifugation and kept at -20°C.
Telemetric measurement of body temperature and locomotor activity
Ten week old female C57BL/6 mice were anesthetized by isoflurane inhalation (1.2-2.0%). An implantable radio frequency transmitter [Data Sciences International (DSI) St. Paul, MN; TA 10ETA-F20] was surgically placed in the peritoneal cavity. Buprenorphine (0.1 mg/kg) was given 15-30min prior to the anticipated recovery time of animals after surgery. The mice were allowed at least 6d to recover before experimentation. The ambient temperature was 24 ± 2°C.
Signals were calibrated to degree Celsius (for temperature) or to counts per minute (for locomotor activity) as recommended by the manufacturer using the software Dataquest A.R.T.™ (DSI, St. Paul, MN). The transmitter signals were recorded intermittently for at least 6d before the actual recording in an experiment. The body temperature and activity patterns were stabilized after this period of acclimation. Mice with transmitters were lightly anesthetized with isofluorane. Groups of eight mice were treated with 1V136 intranasally (i.n.) in 50µl saline, intranasal saline; or LPS 2µg i.p. starting at 9 am. Data for temperature and activity were measured at 10min intervals.
Conditioned taste aversion
A modified method to the previously described protocol was used (14). First mice were individually housed and habituated to water restriction. Mice were conditioned for 2 weeks to scheduled, daily, 2h water access during the light cycle in the test cage . Consumption was measured by the difference between the pre-and post-consumption weight of the total water bottle. Trained mice were given a 0.125% saccharin (Sigma) solution to drink for the first 30 min of fluid access. They were randomly divided into a vehicle treatment group , i.n IV136 500nmoles treatment group , and a subcutaneous lithium chloride (LiCl, 20 mg/kg, Sigma) treatment group. Lithium chloride has been described to produce taste aversion and was used as a control. Each animal was given 3 training sessions in test cages where they were presented with tap water and saccharin solution (0.125%) in two separate bottles. During the third training session the total intake of tap water and saccharin solution was measured 24h after presentation as a baseline. The next day, the mice were given 1h access to saccharin solution only in the test cages, and received the treatments. Following treatment they were presented with a two bottle choice of water and saccharin solutions in the test cages, and their water and saccharin intake was measured for 24h after presentation. The data were expressed as % saccharin-preference {100 x [saccharin intake/(saccharin intake + water intake)]}.
Mast cell reconstitution
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Bone marrow cells were harvested from the femurs and tibia of donors and cultured in RPMI 1640 with 10% FCS (Omega Scientific, Tarzana, CA), 1% penicillin/streptomycin, 0.1mM nonessential amino acids, 5x10 -5 M 2-mercaptoethanol and 3ng/ml IL-3 (BD Biosciences Pharmingen, San Diego CA) for 6 weeks serially monitoring the cultures until they were >95% pure by toluidine blue staining. The recipient W/W(v) mice were injected with 10 7 cells in 100µl RPMI 1640 intravenously. After six weeks of reconstitution the mice were tested for their anorexic response to 1V136.
Cytokine measurements
Serum cytokine levels were measured by multiplex bead assay (LINCO Research, St. Charles, MI) per the manufacturer's recommendations. The lowest limit of detection was 10pg/ml for IL-6, 20pg/ml for TNF , and 15pg/ml for IL-1 . Serum leptin was measured using a commercial ELISA kit from Antigenix America (Huntington Station, NY) and the lower limit of detection was 70pg/ml.
RNA expression in the hypothalamus
After euthanasia, the brain was removed from the skull, leaving the pituitary under the dura, and the ventral surface on top. To remove the hypothalamus, we used the optic chiasm and the rostral edge of the mamillary bodies as rostral and caudal limits, respectively. The hypothalamic sulci were used as lateral limits. The samples were immediately frozen in liquid nitrogen and stored at -80°C. Total RNA were isolated using RNeasy Lipid Tissue Kit (Qiagen, Valencia, CA). Quantity and purity was determined by absorbance using a NanoDrop spectrophotometer.
cDNA was prepared from total RNA (1µg) using an iScript cDNA Synthesis kit (Bio-Rad, Hercules, CA) according to the manufacturer's instructions. All genes of interest were assayed by real-time PCR in a 25µl reaction volume using TaqMan Universal PCR Master Mix and TaqMan Gene Expression Assays (Applied Biosystems, Foster City, CA) using an iCycler IQ (Bio-Rad). All samples were normalized to the housekeeping reference gene 18s RNA ( Ct).
The comparative Ct method was employed to measure fold changes in expression of RNA transcript levels between untreated (t=0h) and drug treated mice for each strain.
Statistical analysis
Data are expressed as mean ± standard error of the mean. The analysis used a paired or unpaired Students' t test for comparing two groups and ANOVA for multiple group comparisons.
Dunnett's post hoc tests were used for multiple comparisons to a control group and Bonferonni post hoc tests for multiple pair-wise comparisons. Telemetric temperature and activity data were analyzed using repeated measures ANOVA under compound symmetry. The complete time course of the data is presented graphically and we indicate statistically significant (Bonferroni corrected) differences for each 10 minute interval on the corresponding graphs. In addition, the 9h of the study period were grouped into 3h periods, and average differences over each period were studied by an ANOVA with main effects for period, treatment, and a period x treatment interaction. If the period x treatment interaction was significant, then treatment effects and 95% confidence intervals are presented within each time period. Statistical significance was assessed at the 5% level.
Results
Intranasal administration of 1V136 suppressed oral intake, enhanced weight loss and induced hypothermia, but did not diminish activity.
LPS, a TLR4 agonist has been well documented to induce behavioral responses known as "sickness behavior" (10). These include decreased locomotor activity, oral intake and dose dependent hypothermia or hyperthermia (30, 31, 45). To assess the physiological effects of the TLR7 agonist, 1V136, mice were treated intranasally with 500nmoles of 1V136 or with vehicle (10% DMSO) alone within the second hour of the light cycle. In preliminary experiments the food intake was measured at 2h, 4h, 6h, 8h and 24h. The control mice consumed less than 10%
of their daily intake within the first 8h (data not shown) and only the 24h time point was assessed in subsequent experiments. During 24h the mice that received 1V136 reduced their food and water intake, and lost weight ( Figure 1A ). The mice recovered their water intake after one day and their food intake and body weight after two days ( Figure 1A ). Intranasal 1V136 did not induce a conditioned taste aversion ( Figure 1B ). There were no significant gender differences in the induction of anorexia by 1V136 (data not shown).
Sickness behavior during inflammation or infection is accompanied by changes in core temperature, as well as anorexia (38). To study the effects of mucosal administration of 1V136 on body temperature, we monitored saline and 1V136 intranasally treated mice for temperature fluctuations over nine hours using implanted radiofrequency transducers ( Figure 1C ). In the analysis, we first grouped the 9h of the study period into three 3h periods and compared temperature between treatments averaged over these 3h periods. In a two-way repeated measures ANOVA, treatment (p=0.03), period (p<0.001), and treatment x period (p<0.001) were significant, indicating that temperature differences between treatments were not the same for the Page 11 of 38 three time periods studied. In a more detailed analysis, we examined differences in each 10-minute period using the same repeated measures ANOVA with a Bonferroni correction.
Estimating treatment differences averaged over each 3h period showed a statistically significant decrease in temperature for the 1V136 treated mice as compared to saline during the first 3h period (mean difference 1V136 -saline -0.80 (95% CI -1.57, -.04) while temperature in the LPS mice was increased, although not significantly so, compared to controls (mean difference 0.33; 95% CI -0.46, 1.11). Detailed analysis showed temperature in the LPS mice to be significantly elevated during the beginning of the 3h period, and significantly decreased at the end of the 3h period ( Figure 1C ). From 3h to 6h post-injection, average temperature was significantly The activity of the mice was also recorded ( Figure 1D ). In a similar two-way repeated measures ANOVA, treatment (p=0.03), period (p=0.005), and treatment x period (p=0.002) were significant, indicating that treatment differences were not the same across the three time periods studied. Estimating treatment differences within each period showed a small and non-significant increase in activity for the 1V136 treated mice as compared to saline during the first 3h period 
Mucosal administration more potently induced anorexia than systemic injection
Initially the biologically effective doses of intranasal 1V136 were identified by dose titration. A lower dose of 50nmoles however did not have an anorectic response (data not shown). Doses of 150 and 500nmoles administered to mice intranasally resulted in anorexic behavior and weight loss over a 24h period (Figures 2A and B) . A lower dose of 50nmoles i.n., however, did not elicit an anorexic response or weight loss (data not shown). We then tested the effect of different routes of exposure to the TLR7 agonist by administering 1V136 intraperitoneally (i.p.), intragastrically (i.g.), or intranasally (i.n.). All routes differed significantly from control at the 500nmole dose, and all but i.p. at the 150nmole dose (Dunnet's comparsons vs control, p<0.01). In a two-way ANOVA, dose and treatment were significant (p <0.01), but the interaction term was not (p>0.50). Mucosal delivery by either i.n. or i.g. routes resulted in weight loss relative to i.p. administration (p<0.001), but the two mucosal routes, i.n. and i.g. did not differ significantly from each other (p = 0.64) (Figure 2A ). Results for 24h weight loss were similar ( Figure 2B ).
Pro-inflammatory cytokines, such as IL-6 and TNF , are induced by TLR ligation and are known to cause anorexia (11). In mice treated with 150nmoles of 1V136 i.p. or i.n., the peripheral serum levels peaked 2h after either route of administration (Table 1) . Although anorexic behavior induced by 150nmoles of 1V136 was greater in the i.n. treated group than in the i.p. injected group, the peak levels of serum cytokines were higher in the i.p. treated group (p<0.05). For comparison, i.p. LPS also resulted in a significant rise in systemic IL-6 and TNF also peaking at 2h. An increase in the appetite suppressant leptin has been implicated in LPS induced anorexia (15, 48) . The level of leptin roughly doubled in the serum of i.n. treated 1V136 mice peaking by 6h, similar to the LPS treated mice.
1V136 induced anorexia is mediated by the TLR7 and MyD88 pathway
We previously demonstrated the TLR7 specificity of 1V136 in antiviral activity (37). To examine whether the 1V136 induced anorexic response was also induced via the TLR7 pathway, we administered 1V136 to various TLR deficient mice. All mice received 500nmoles 1V136 i.n., and food intake and body weight were monitored for 24h. TLR7 -/-and MyD88 -/-showed significantly less anorexia, whereas the TLR4 -/-and TLR9 -/-mice reduced their food intake and lost weight (not shown) similar to wild type mice ( Figure 3A) .
Mediators of the anorexic effects of 1V136
Several pro-inflammatory cytokines and endocrine hormones have been suggested as mediators in anorexia induced by inflammation or infections (11, 58). Specifically, leptin, IL-1 , IL-6, and TNF have been described to mediate TLR4 induced anorexia (15, 26, 48, 58, 60 Figure 3B ). Mice that were leptin deficient (ob/ob) mice demonstrated an enhanced anorexic response to 1V136 ( Figure 3B ). In contrast, TNF deficient mice were relatively refractory to the compound ( Figure 3B ).
To further examine the central response of intranasal 1V136, the hypothalami of treated mice were removed at 0h, 2h, 6h, 12h, 24h and 48h post-treatment ( Figure 3C ). The mRNA expression levels of key inflammatory cytokines were measured by quantitative PCR and the relative increases were compared to the baseline levels ( Figure 3C ). There was an increase in the level of TNF mRNA that diminished with time but remained greater than two fold up to 24h in the hypothalami of 1V136 treated mice. In contrast there was a more modest five fold increase in IL-1 mRNA that rapidly declined to approximately two fold after 6h. The levels of TNF and IL-1 mRNA in 1V136 treated MyD88 and TLR7 mice remained less than two fold that of untreated mice. There was no measurable increase in IL-6 mRNA levels (data not shown).
Another potential central nervous system mediator of 1V136 associated hypophagia and anorexia is prostaglandin E2 (PGE2) and other prostanoids (4). The cyclo-oxygenases (COX)
are essential in the central and peripheral production of PGE2. In mutant mice deficient in the inducible form of cyclo-oxygenase, COX-2, the effect of TLR7 stimulation was diminished, but not in COX-1 deficient mice ( Figure 3D ). Recently, connective tissue mast cells have been reported to release pro-inflammatory cytokines and chemokines upon TLR7 ligation (42). As mucosal administration of 1V136 was more potent than systemic administration (Figure 2A and B), we hypothesized that connective tissue mast cells located near the mucosal surface might be involved in TLR7-induced anorexia.
Anorexic behavior induced by 1V136 is attenuated in
We therefore tested the anorexic response of W/W(v) mice, which are tissue mast cell-deficient, or control mice (W/W +/+ ) to two doses of i.p. LPS ( Figure 4C ). The W/W(v) mice had a diminished response to the lower dose of LPS (2µg). They reduced their food intake to a comparable level to the wild type mice when receiving the higher dose (20µg) but they started with lower food intake overall.
We then compared the responses of the W/W(v) mice, and the control mice (W/W +/+ ) to intranasal 1V136. The W/W(v) mice showed approximately 25% resistance to this compound compared to the controls ( Figure 4D ). Reconstitution of the mast cell deficient mice with wild type mast cells recapitulated the wild type response to 1V136 ( Figure 4D ). The effects in the mast cell deficient mice could partially be attributed to changes in peripheral serum TNF or IL-6, as there was a trend for these cytokines to be lower in the 1V136 treated W/W(v) mice compared to controls (Table 2 ). Serum IL-1 levels were below the reliable detection limit.
In addition to cytokines, histamine is a signature effector molecule released during mast cell degranulation, and some of the histamine receptors contribute to behavioral changes in animals (43, 53). We therefore, injected histamine receptor antagonists, chlorpheniramine maleate (CM, H1 receptor antagonist), cimetidine (CIM, H1/H2 receptor antagonist), and a mast cell stabilizer, cromolyn sodium (CROM), prior to 1V136 administration ( Figure 4E ). The mast cell membrane stabilizing agent reduced the anorexic effects of the TLR7 agonist, while the histamine receptor antagonists were ineffective.
Discussion
Microbial infection is often accompanied by sickness behavior that includes fever, anorexia, and lethargy. These reactions are considered as active and adaptive responses initiated by the immune system that produce temporary suspension of normal homeostasis to facilitate clearance of pathogens and return to normal status (4). During the first stage of a microbial infection, mammalian TLRs play a major role as sensors for invasion of infectious agents and activate the innate immune system (55). TLR-induced pro-inflammatory cytokines secreted by the activated immune cells are known to reduce animals' motivation for food intake (10, 26, 57).
Here, we showed that the mucosal administration of a low molecular weight synthetic TLR7 ligand, 1V136, induced temporary anorexia via the TLR7/MyD88 pathway. The hypophagia and hypodipsia were accompanied by hypothermia, and a reduction in locomotor activity (Figure 1 ).
Mucosal delivery of 1V136 did not induce a conditioned taste aversion as 1V136 treated mice preferred water with 0.125% saccharin at similar levels to vehicle treated mice ( Figure 1B ). (Table 1) . This difference suggests that cytokines in the central nervous system might have played system predominant role in producing anorexia following mucosal TLR7 stimulation.
1V136 is an orally available compound, and gastric administration resulted in significant anorexia at 150nmoles (Figure 2) . The anorexia at this dose was greater for oral than for i.p.
administration. Both routes of mucosal administration (i.n. and i.g.) of 1V136 were found to exert more potent behavioral effects than systemic administration of the same drug (Figure 2 ). However, COX-1 did not significantly impact the overall anorexia response. In LPS and IL-1 induced hypophagia, COX-1 might effect behavior immediately after stimulation; whereas COX-2 plays the predominant role later in the response (25, 39, 50, 51). In our studies we are not able to discern whether these effects were centrally or peripherally mediated, as we used mutant mice that do not express any of the targeted mediators.
Perspectives and Significance
Innate immune stimulation by TLR7 agonists has been proposed as a systemic treatment for cancer, atopic and infectious diseases (9, 19). As shown here, however, pharmacologic activation of TLR7 can also produce transient anorexia and hypothermia, mediated in part by proinflammatory cytokines that are released by tissue mast cells, and that act centrally as well as peripherally. Pharmacologic stabilization of mast cells may diminish the anorexia and temperature fluxes that are potentially induced by TLR7 activation, while permitting activation of other components of the immune system.
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